logo

Alnylam Pharmaceuticals Inc. (ALNY)



Trade ALNY now with
  Date
  Headline
6/18/2019 8:05:00 AM Alnylam Announces Approval In Japan Of ONPATTRO For Hereditary ATTR Amyloidosis With Polyneuropathy
6/17/2019 7:16:31 AM Alnylam Reports Full Patient Enrollment In ILLUMINATE-A Phase 3 Study
6/17/2019 7:06:50 AM Alnylam Completes Enrollment For ILLUMINATE-A Phase 3 Study Of Lumasiran In Patients With PH1
6/13/2019 8:06:48 AM Alnylam To Report New Clinical Results For ONPATTRO At Peripheral Nerve Society Annual Meeting And EAN
6/5/2019 7:20:55 AM Alnylam Completes Rolling Submission Of NDA To FDA For Givosiran
5/31/2019 7:06:59 AM Alnylam Doses First Patient In Phase 1 Study Of ALN-AGT For The Treatment Of Hypertension
5/29/2019 8:07:19 AM Alnylam Appoints Kelley Boucher As SVP, CHRO And Kevin Fitzgerald SVP, CSO
5/1/2019 8:17:34 AM Alnylam Pharma Q1 GAAP Loss/Shr $1.73; Non-GAAP Loss/Shr $1.42
4/15/2019 7:15:57 AM Alnylam Begins ILLUMINATE-B Phase 3 Pediatric Study Of Lumasiran
4/8/2019 7:01:41 AM Regeneron And Alnylam Collaborate To Discover, Develop And Commercialize New RNAi Therapeutics
4/8/2019 1:03:11 AM Alnylam And Sanofi Conclude Research And Option Phase Of 2014 RNAi Therapeutics Collaboration
3/27/2019 7:05:11 AM Alnylam To Present Givosiran Phase 3 Data At EASL International Liver Congress
3/6/2019 7:10:28 AM Alnylam Posts Positive Topline Results From ENVISION Phase 3 Study Of Givosiran
2/7/2019 5:11:25 PM Alnylam Pharma Q4 Loss/share $2.09 Vs. Loss $1.48 Year Ago
2/6/2019 5:02:43 PM Alnylam Reports Publication Of Phase 1 Givosiran Data In The New England Journal Of Medicine
1/23/2019 8:01:15 AM CAMP4 Therapeutics Announces Rare Disease Research Collaboration With Alnylam